Skip to main content

Ziresovir Reduces Signs, Symptoms of Bronchiolitis in Babies With RSV

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 27, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Sept. 27, 2024 -- For infants and young children hospitalized with respiratory syncytial virus (RSV) infection, ziresovir reduces signs and symptoms of bronchiolitis, according to a study published in the Sept. 26 issue of the New England Journal of Medicine.

Shunying Zhao, M.D., Ph.D., from Beijing Children's Hospital, and colleagues enrolled participants aged 1 to 24 months of age who were hospitalized with RSV infection in a phase 3, multicenter trial. Participants were randomly assigned to receive ziresovir (10 to 40 mg according to body weight) or placebo, administered twice daily for five days in a 2:1 ratio. A total of 244 participants were included in the intention-to-treat population, and the safety population included 302 participants.

The researchers observed a significantly greater reduction from baseline in the Wang bronchiolitis clinical score at day 3 with ziresovir than with placebo (−3.4 versus −2.7 points). At day 5, the reduction in the RSV viral load was greater in the ziresovir group than the placebo group (−2.5 versus −1.9 log10 copies/mL). Prespecified subgroups, including those with a baseline bronchiolitis score of at least 8 and those aged 6 months or younger, showed improvements. The incidence rates of adverse events related to the drug or placebo were 16 and 13 percent, respectively.

"Ziresovir treatment in infants and young children who were hospitalized with RSV infection resulted in a significantly greater resolution of signs and symptoms associated with RSV infection as well as greater decrease in the viral load than placebo," the authors write.

The study was funded by Shanghai Ark Biopharmaceutical, which is developing ziresovir.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2024

Read this next

RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization

TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...

Nirsevimab Effective for Reducing Burden of RSV in Infants

THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...

72 Percent of Infants Immunized Against Respiratory Syncytial Virus

TUESDAY, May 6, 2025 -- In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be immunized against respiratory...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.